The biological mechanism underlying the higher CRC risk in the MSH2 mutation carriers may be due to the functional role of MSH2, which is to proofread a newly synthesized DNA strand for mismatch base-pair and insertion-deletion mutations that occur during DNA replication20. This evidence concerns the gene MSH2 and colorectal carcinoma.